We have located links that may give you full text access.
Journal Article
Review
An update in the nonendoscopic treatment of gastric cancer.
Current Opinion in Gastroenterology 2016 November
PURPOSE OF REVIEW: This article reviews the recent seminal studies in esophagogastric cancer.
RECENT FINDINGS: Regular low aspirin use may reduce the risk of esophagogastric cancer. Laparoscopic resection of locally advanced gastric cancer appears equivalent to open resection. There is no survival benefit for the addition of postoperative radiation therapy to adjuvant chemotherapy after primary gastric cancer resection. For tumors of the esophagus and gastroesophageal junction, the combination of preoperative radiation therapy with concurrent chemotherapy may be required to ensure achievement of a negative surgical margin and to reduce local tumor recurrence. Epirubicin may not add benefit to fluorinated pyrimidine and platinum-based chemotherapy, either in the preoperative setting or in the treatment of metastatic disease. The Her2-targeted agents lapatinib and trastuzumab emtansine failed to improve outcome when either added to or compared with chemotherapy. Immune checkpoint inhibition appears to be active in metastatic gastric cancer.
SUMMARY: Recent studies in esophagogastric cancer help clarify the role of radiation therapy in surgical management, as well as the role of chemotherapeutic and targeted agents.
RECENT FINDINGS: Regular low aspirin use may reduce the risk of esophagogastric cancer. Laparoscopic resection of locally advanced gastric cancer appears equivalent to open resection. There is no survival benefit for the addition of postoperative radiation therapy to adjuvant chemotherapy after primary gastric cancer resection. For tumors of the esophagus and gastroesophageal junction, the combination of preoperative radiation therapy with concurrent chemotherapy may be required to ensure achievement of a negative surgical margin and to reduce local tumor recurrence. Epirubicin may not add benefit to fluorinated pyrimidine and platinum-based chemotherapy, either in the preoperative setting or in the treatment of metastatic disease. The Her2-targeted agents lapatinib and trastuzumab emtansine failed to improve outcome when either added to or compared with chemotherapy. Immune checkpoint inhibition appears to be active in metastatic gastric cancer.
SUMMARY: Recent studies in esophagogastric cancer help clarify the role of radiation therapy in surgical management, as well as the role of chemotherapeutic and targeted agents.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app